Showing results (1-10 of 15) with videos related to
Sort By:
Pageof 2
Ciba Foundation Symposium|January 1, 1987
The significance of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridineC D Marsden, P G JennerNeurology|June 20, 1998
Levodopa neurotoxicity: experimental studies versus clinical relevanceP G Jenner, M F BrinTrends in Pharmacological Sciences|November 5, 1997
Adenosine A2A receptor antagonists as new agents for the treatment of Parkinson's diseaseP J Richardson, H Kase, P G JennerBritish Journal of Clinical Pharmacology|May 1, 1978
The effect of low dose carbidopa/levodopa on prolactin and growth hormone concentrations in patients with breast cancer and in benign breast tumoursM K Jones, I D Ramsay, P G JennerNaunyn-Schmiedeberg'S Archives of Pharmacology|March 29, 1977
The interaction of clonidine with dopamine-dependent behaviour in rodentsC J Pycock, P G Jenner, C D MarsdenNeuroscience|January 5, 2000
Effect of unilateral 6-hydroxydopamine lesions of the nigrostriatal pathway on GABA(A) receptor subunit gene expression in the rodent basal ganglia and thalamusA Chadha, L G Dawson, P G Jenner, et al.The Journal of Pharmacy and Pharmacology|March 1, 1997
Comparison of HPLC and enzymatic recycling assays for the measurement of oxidized glutathione in rat brainJ Sian, D T Dexter, G Cohen, et al.Acta Neurologica Scandinavica|August 1, 1992
Debrisoquine hydroxylation in Parkinson's diseaseM J Steiger, P Lledo, N P Quinn, et al.Neuropharmacology|August 1, 1986
MPP+ can disrupt the nigrostriatal dopamine system by acting in the terminal areaA J Bradbury, B Costall, P G Jenner, et al.Neuroscience Letters|July 31, 1985
The neurotoxic actions of 1-methyl-4-phenylpyridine (MPP+) are not prevented by deprenyl treatmentA J Bradbury, B Costall, P G Jenner, et al.Pageof 2